Trial
NCT00005987
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
—
Condition
Multiple Myeloma and Plasma Cell Neoplasm
Intervention
carmustine
Why stopped
Withdrawn because treatment guidelines changed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-29